PubRank

MorbiMortality Amelioration in Preeclamptic Primiparas Study. MoMA Pre Prim Study (MOMA)

Clinical Trial ID NCT00763672

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00763672

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004 14.00
2 Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003 13.72
3 Pre-eclampsia. Lancet 2005 10.41
4 A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008 3.39
5 Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 2003 3.36
6 Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia. Endocrinology 2004 2.83
7 Urinary placental growth factor and risk of preeclampsia. JAMA 2005 2.76
8 Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab 2003 1.88
9 Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia. Clin Chem 2004 1.16
10 Soluble VEGF receptor Flt1: the elusive preeclampsia factor discovered? J Clin Invest 2003 1.04
11 Soluble fms-like tyrosine kinase 1. N Engl J Med 2004 0.82
12 Pattern and factors affecting the outcome of pregnancy in hypertensive patients. J Natl Med Assoc 2004 0.75
13 Hypertensive disorders of pregnancy: future perspectives. A French point of view. Curr Opin Obstet Gynecol 2008 0.75
Next 100